References
- Barratt J, Kim SG, Agha I et al. (2023) WNC 23-1175 updated interim results of a phase 1/2 study of bion-1301 in patients with IgA nephropathy. Kidney Int Rep 8:S280–S281.
https://doi.org/10.1016/j.ekir.2023.02.632 - Benson MJ, Dillon SR, Castigli E et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655–3659.
https://doi.org/10.4049/jimmunol.180.6.3655 - Bosello S, Youinou P, Daridon C et al. (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264.
- Bowman SJ, Fox R, Dörner T et al. (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399:161–171.
https://doi.org/10.1016/S0140-6736(21)02251-0 - Cai J, Gao D, Liu D et al. (2023) Telitacicept for autoimmune nephropathy. Front Immunol 14:1169084.
https://doi.org/10.3389/FIMMU.2023.1169084 - Cao Y, Lu G, Chen X et al. (2020) BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF κB signaling pathway in glomerular mesangial cells. Mol Med Rep 21:795–805.
https://doi.org/10.3892/MMR.2019.10870 - Caza TN, Storey AJ, Hassen SI et al. (2023) Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int 103:593–606.
https://doi.org/10.1016/j.kint.2023.01.001 - Chan J, Walters GD, Puri P et al. (2023) Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol 7:37.
https://doi.org/10.1186/S41927-023-00358-3 - Cheung CK, Barratt J, Liew A et al. (2024) The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol 3:1346769.
https://doi.org/10.3389/FNEPH.2023.1346769 - Currie EG, Coburn B, Porfilio EA et al. (2022) Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight 7:e141289.
https://doi.org/10.1172/jci.insight.141289 - Evans LS, Lewis KE, DeMonte D et al. (2023) Povetacicept, an enhanced dual APRIL/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol 75:1187–1202.
https://doi.org/10.1002/art.42462 - Feng J, HU Y, Chang AH et al. (2023) CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus – safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835.
https://doi.org/10.1182/blood-2023-186669 - Figgett WA, Deliyanti D, Fairfax KA et al. (2015) Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J Autoimmun 61:9–16.
https://doi.org/10.1016/j.jaut.2015.04.007 - Forero-Delgadillo J, Ochoa V, Restrepo JM et al. (2022) B-cell activating factor (BAFF) and its receptors' expression in pediatric nephrotic syndrome is associated with worse prognosis. PLoS One 17:e0277800.
https://doi.org/10.1371/journal.pone.0277800 - Furie RA, Aroca G, Cascino MD et al. (2022a) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100–107.
https://doi.org/10.1136/annrheumdis-2021-220920 - Furie R, Petri M, Zamani O et al. (2011) A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Reum 63:3918–3930.
https://doi.org/10.1002/ART.30613 - Furie R, Rovin BH, Houssiau F et al. (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128.
https://doi.org/10.1056/NEJMoa2001180 - Furie R, Rovin BH, Houssiau F et al. (2022b) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17:1620–1630.
https://doi.org/10.2215/CJN.02520322 - Furie RA, Rovin BH, Garg JP et al. (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471–1483.
https://doi.org/10.1056/NEJMoa2410965 - Gabay C, Krenn V, Bosshard C et al. (2009) Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 11:R144.
https://doi.org/10.1186/ar2817 - Gordon C, Bassi R, Chang P et al. (2019) Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract 3:rkz021.
https://doi.org/10.1093/rap/rkz021 - Groom JR, Fletcher CA, Walters SN et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959–1971.
https://doi.org/10.1084/jem.20062567 - Han SS, Yang SH, Jo HA et al. (2018) BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. Oncotarget 9:3292–3302.
https://doi.org/10.18632/Oncotarget.23232 - Huang SP, Snedecor SJ, Nanji S et al. (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: A systematic literature review. Rheumatol Ther 9:975–991.
https://doi.org/10.1007/S40744-022-00454-9 - Huard B, Tran NL, Benkhoucha M et al. (2012) Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 7:e31837.
https://doi.org/10.1371/journal.pone.0031837 - Jacob CO, Yu N, Sindhava V et al. (2015) Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors. Arthritis Rheumatol 67:2523–2535.
https://doi.org/10.1002/art.39210 - Jin HZ, Cai ML, Wang X et al. (2025) Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol 44:247–256.
https://doi.org/10.1007/s10067-024-07266-y - Khare SD, Sarosi I, Xia XZ et al. (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97:3370–3375.
https://doi.org/10.1073/pnas.97.7.3370 - Kiryluk K, Li Y, Scolari F et al. (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196.
https://doi.org/10.1038/ng.3118 - Kiyama K, Kawabata D, Hosono Y et al. (2012) Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther 14:R86.
https://doi.org/10.1186/ar3810 - Lafayette R, Barbour S, Israni R et al. (2024) A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int 105:1306–1315.
https://doi.org/10.1016/j.kint.2024.03.012 - Lafayette RA, Canetta PA, Rovin BH et al. (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313.
https://doi.org/10.1681/asn.2016060640 - Li Z, Chen P, Zhang Y et al. (2024) Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy. Ren Fail 46:2391069.
https://doi.org/10.1080/0886022X.2024.2391069 - Luo Y, Qie Y, Gadd ME et al. (2023) Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies. Cancer Immunol Immunother 72:4031–4047.
https://doi.org/10.1007/S00262-023-03537-w - Lv J, Liu L, Hao C et al. (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499–506.
https://doi.org/10.1016/j.ekir.2022.12.014 - Mackensen A, Müller F, Mougiakakos D et al. (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124–2132.
https://doi.org/10.1038/s41591-022-02017-5 - Marín-Rosales M, Palafox-Sánchez CA, Franco-Topete RA et al. (2022) Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis. J Clin Med 12:71.
https://doi.org/10.3390/jcm12010071 - Mathur M, Barratt J, Chacko B et al. (2024) A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. New Engl J Med 390:20–31.
https://doi.org/10.1056/NEJMOA2305635 - Mathur M, Chan TM, Oh KH et al. (2023) A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence. J Clin Med 12:6927.
https://doi.org/10.3390/jcm12216927 - McCarthy DD, Kujawa J, Wilson C et al. (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991–4002.
https://doi.org/10.1172/JCI45563 - Mo S, Li Y, He J et al. (2024) Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Front Med 11:1472019.
https://doi.org/10.3389/fmed.2024.1472019 - Mougiakakos D, Krönke G, Völkl S et al. (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567–569.
https://doi.org/10.1056/NEJMc2107725 - Mucha K, Pac M, Pączek L (2023) Omics are getting us closer to understanding IgA nephropathy. Arch Immunol Ther Exp 71:12.
https://doi.org/10.1007/S00005-023-00677-w - Nawata A, Nakayamada S, Hisano S et al. (2023) Original research: differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus Sci Med 10:e000962.
https://doi.org/10.1136/lupus-2023-000962 - Netti GS, Infante B, Spadaccino F et al. (2019) Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy. J Immunol Res 2019:8483650.
https://doi.org/10.1155/2019/8483650 - Neusser MA, Lindenmeyer MT, Edenhofer I et al. (2011) Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24:98–107.
https://doi.org/10.1038/modpathol.2010.184 - Oniszczuk J, Beldi-Ferchiou A, Audureau E et al. (2021) Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 36:609–617.
https://doi.org/10.1093/ndt/gfaa279 - Petrou D, Kalogeropoulos P, Liapis G et al. (2023) IgA nephropathy: current treatment and new insights. Antibodies 12:40.
https://doi.org/10.3390/antib12020040 - Piantoni S, Korsten P (2022) Rituximab-a B cell targeted therapy in systemic lupus erythematosus: where do we stand? Rheumatology 61:1752–1755.
https://doi.org/10.1093/rheumatology/keac095 - Roos I, Hughes S, McDonnell G et al. (2023) Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 80:789–797.
https://doi.org/10.1001/jamaneurol.2023.1625 - Sallustio F, Curci C, Chaoul N et al. (2021) High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant 36:452–464.
https://doi.org/10.1093/ndt/gfaa264 - Samy E, Wax S, Huard B et al. (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36:3–19.
https://doi.org/10.1080/08830185.2016.1276903 - Selvaskandan H, Barratt J, Cheung CK (2023) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9:203–213.
https://doi.org/10.1016/j.ekir.2023.11.026 - Suzuki H, Kiryluk K, Novak J et al. (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803.
https://doi.org/10.1681/asn.2011050464 - Trimarchi H, Barratt J, Radhakrishnan J et al. (2024) WCN24-1837 beyond: a phase 3, randomized, double-blind, placebo controlled trial of zigakibart in adults with IgA nephropathy. Kidney Int Rep 9:S177.
https://doi.org/10.1016/j.ekir.2024.02.362 - Union Register of Medicinal Products – Public Health – European Commission. (2024) Union register of medicinal products for human use.
https://ec.europa.eu/health/documents/community-register/html/h067.htm . Accessed 25 November 2024. - Vosters JL, Roescher N, Polling EJ et al. (2012) The expression of APRIL in Sjögren's syndrome: aberrant expression of APRIL in the salivary gland. Rheumatology (Oxford) 51:1557–1562.
https://doi.org/10.1093/RHEUMATOLOGY/KES080 - Wallace DJ, Isenberg DA, Morand EF et al. (2021) Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology 60:5379–5389.
https://doi.org/10.1093/rheumatology/keab115 - Wang W, He S, Zhang W et al. (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83:1304–1314.
https://doi.org/10.1136/ARD-2024-225785 - Wang X, Dong Z, Awuah D et al. (2022) CD19/BAFF-R dual-targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia 36:1015–1024.
https://doi.org/10.1038/S41375-021-01477-X - Wong DP, Roy NK, Zhang K et al. (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 13:217.
https://doi.org/10.1038/s41467-021-27853-w - Worley K, Milligan S, Rubin B (2023) Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Sci Med 10:e001024.
https://doi.org/10.1136/LUPUS-2023-001024 - Xiao X, Huang S, Chen S et al. (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 40:367.
https://doi.org/10.1186/S13046-021-02148-6 - Xin G, Shi W, Xu LX et al. (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683–690.
https://doi.org/10.5301/JN.5000218 - Yu XQ, Li M, Zhang H et al. (2011) A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44:178–182.
https://doi.org/10.1038/NG.1047 - Zhai YL, Zhu L, Shi SF et al. (2016) Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore) 95:e3099.
https://doi.org/10.1097/MD.0000000000003099 - Zhang L, Jin H, Wang D et al. (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol 14:1268929.
https://doi.org/10.3389/fimmu.2023.1268929 - Zheng N, Wang D, Ming H et al. (2015) BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol 16:72.
https://doi.org/10.1186/S12882-015-0064-y - Zhuang Y, Lu H, Li J (2023) Advances in the treatment of IgA nephropathy with biological agents. Chronic Dis Transl Med 10:1–11.
https://doi.org/10.1002/CDT3.104